Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to $415.5 million.

  • Theravance Biopharma's Liabilities and Shareholders Equity rose 1666.78% to $415.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 460.76%. This contributed to the annual value of $354.2 million for FY2024, which is 728.75% down from last year.
  • Per Theravance Biopharma's latest filing, its Liabilities and Shareholders Equity stood at $415.5 million for Q3 2025, which was up 1666.78% from $426.0 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's Liabilities and Shareholders Equity peaked at $763.5 million during Q3 2022, and registered a low of $343.6 million during Q1 2025.
  • Over the past 5 years, Theravance Biopharma's median Liabilities and Shareholders Equity value was $382.0 million (recorded in 2023), while the average stood at $425.2 million.
  • In the last 5 years, Theravance Biopharma's Liabilities and Shareholders Equity skyrocketed by 8940.19% in 2022 and then tumbled by 4582.94% in 2023.
  • Quarter analysis of 5 years shows Theravance Biopharma's Liabilities and Shareholders Equity stood at $374.8 million in 2021, then skyrocketed by 62.05% to $607.4 million in 2022, then plummeted by 37.11% to $382.0 million in 2023, then dropped by 7.29% to $354.2 million in 2024, then increased by 17.31% to $415.5 million in 2025.
  • Its Liabilities and Shareholders Equity was $415.5 million in Q3 2025, compared to $426.0 million in Q2 2025 and $343.6 million in Q1 2025.